Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG003 in neovascular age-related macular degeneration
NCT00607750Phase 2Completed
- Sponsor
- CoMentis, Inc.
- Start
- May 2008
- Primary completion
- Apr 2010
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of mecamylamine in neovascular age-related macular degeneration (NVAMD), sponsored by CoMentis, Inc.. Started May 2008; status: completed.
02
Drugs
mecamylamine
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00607750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00607750.